Brookline Capital Markets Comments on Oncobiologics Q1 Earnings

Key Points

• Brookline Capital Markets expects Oncobiologics to report a Q1 2027 loss of $0.05 per share, with projected losses of $0.03 per share in each of the following two quarters. Full-year consensus earnings are estimated at a $0.49-per-share loss.
• Analyst sentiment is mixed: two analysts rate the stock Buy, four Hold and one Sell, resulting in a consensus Hold rating and an average price target of $4.65.
• Oncobiologics recently missed quarterly expectations, reporting a $0.09-per-share loss versus the anticipated $0.08 loss and only $10,000 in revenue versus $970,000 expected. Shares opened at $0.69, while insiders bought more than 11.1 million shares over the past three months.

Oncobiologics, Inc. (NASDAQ:OTLK - Free Report) - Analysts at Brookline Capital Markets issued their Q1 2027 earnings estimates for shares of Oncobiologics in a research report issued to clients and investors on Tuesday, August 18th. Brookline Capital Markets analyst K. Dolliver anticipates that the company will post earnings of ($0.05) per share for the quarter. The consensus estimate for Oncobiologics' current full-year earnings is ($0.49) per share. Brookline Capital Markets also issued estimates for Oncobiologics' Q2 2027 earnings at ($0.03) EPS and Q3 2027 earnings at ($0.03) EPS.

OTLK has been the topic of a number of other research reports. Ascendiant Capital Markets increased their price objective on Oncobiologics from $6.00 to $10.00 and gave the company a "buy" rating in a report on Thursday, June 11th. Weiss Ratings upgraded Oncobiologics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, August 12th. BTIG Research reiterated a "buy" rating and issued a $4.00 price target on shares of Oncobiologics in a research note on Friday, August 14th. HC Wainwright raised their price objective on shares of Oncobiologics to $1.60 and gave the stock a "neutral" rating in a report on Monday, July 27th. Finally, Wall Street Zen downgraded shares of Oncobiologics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Oncobiologics has a consensus rating of "Hold" and an average price target of $4.65.

Oncobiologics Price Performance

Shares of NASDAQ OTLK opened at $0.69 on Thursday. The company has a market cap of $102.54 million, a price-to-earnings ratio of -0.90 and a beta of 0.82. The stock's 50-day moving average is $1.31 and its two-hundred day moving average is $0.71. Oncobiologics has a 1-year low of $0.16 and a 1-year high of $3.39.

Oncobiologics (NASDAQ:OTLK - Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The company had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.97 million.

Insider Buying and Selling

In related news, Director Faisal Ghiath Sukhtian purchased 95,398 shares of Oncobiologics stock in a transaction dated Wednesday, July 29th. The stock was bought at an average cost of $1.05 per share, for a total transaction of $100,167.90. Following the transaction, the director owned 220,972 shares in the company, valued at approximately $232,020.60. The trade was a 75.97% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ghiath M. Sukhtian acquired 8,539,709 shares of Oncobiologics stock in a transaction that occurred on Thursday, May 28th. The shares were purchased at an average cost of $0.59 per share, with a total value of $5,038,428.31. Following the completion of the acquisition, the director owned 22,092,068 shares of the company's stock, valued at $13,034,320.12. The trade was a 63.01% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 11,189,359 shares of company stock valued at $7,662,666. Company insiders own 1.80% of the company's stock.

Hedge Funds Weigh In On Oncobiologics

Several hedge funds have recently bought and sold shares of OTLK. Goldman Sachs Group Inc. grew its position in Oncobiologics by 74.1% during the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company's stock valued at $126,000 after acquiring an additional 44,063 shares during the period. AQR Capital Management LLC increased its stake in Oncobiologics by 42.7% during the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company's stock worth $103,000 after acquiring an additional 25,351 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in shares of Oncobiologics by 865.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company's stock worth $39,000 after purchasing an additional 21,941 shares during the period. Hedge funds and other institutional investors own 11.20% of the company's stock.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics' research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source